Concord Biotech Limited (BOM:543960)

Market Cap	157.52B
Revenue (ttm)	10.89B
Net Income (ttm)	3.26B
Shares Out	n/a
EPS (ttm)	31.19
PE Ratio	48.28
Forward PE	36.94
Dividend	8.75 (0.57%)
Ex-Dividend Date	n/a

Volume	22,758
Average Volume	10,646
Open	1,440.05
Previous Close	1,533.65
Day's Range	1,432.00 - 1,556.80
52-Week Range	1,326.90 - 2,658.00
Beta	n/a
RSI	43.15
Earnings Date	May 23, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,377
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543960

Financial Performance

In 2023, Concord Biotech's revenue was 10.17 billion, an increase of 19.20% compared to the previous year's 8.53 billion. Earnings were 3.08 billion, an increase of 28.33%.